Hyphens Pharma focuses on the sales and marketing of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States.
Established presence in the region
ASEAN is a growing market with more than 600 million people. With a rising middle-income group, it is the third-most populous region in the world, after South Asia and East Asia. According to a 2018 White Paper by Solidance, the total healthcare spending for six major ASEAN economies – Singapore, Malaysia, Vietnam, Indonesia, the Philippines and Thailand – is forecasted to rise to USD 740 billion (2025) from USD 420 billion (2017).
The demand for quality healthcare products will grow in tandem. With our competent sales and marketing teams and strong in-house regulatory capabilities, Hyphens Pharma is well-positioned to capture this growth opportunity. We operate directly in Singapore (HQ), Malaysia, Vietnam, Indonesia and the Philippines.
World class premium products for the betterment of lives
In part of our vision to provide a better quality of life to patients, we are constantly on the pulse of our industry’s innovation to meet patients’ needs. Over time, we have developed significant experience in certain therapeutic areas or medical specialties. We bring in specialty pharmaceutical products around these areas such as dermatology, paediatrics and neonatology, allergy, otorhinolaryngology (ear, nose and throat), orthopaedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry and family medicine.
The major products in our product portfolio include contrast media products, Stérimar® nasal sprays, Bausch+Lomb eye drops, Vivomixx™, Fenosup® Lidose® and Piascledine®.
In addition, Hyphens Pharma develops, markets and sells our proprietary range of dermatological products marketed under our Ceradan® and TDF® brands, health supplement products marketed under our Ocean Health® brand, and scalp care products marketed under CG 210® brand.
Together, we can improve the healthcare of this world
Hyphens Pharma is a part of the Hyphens Group.
Listed on the Catalist board of Singapore Exchange (SGX), Hyphens Group has a total turnover of SGD 162.3 million in 2022. Our flat organizational structure allows for nimble decision-making and navigation through unique cultural, political, social and regulatory environment of the country we operate in.